Vinay Prasad returns as FDA’s CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.
Vinay Prasad’s Comeback To FDA Sparks Debate Over Regulatory Direction
Where Today's News Shapes Tomorrow
March 4, 2026
Headlines
